• Home
• Learning Centers
• Diseases & Conditions
• Drugs
• Symptoms
• Videos
• Health Experts
• Tools
• Marketplace

• Basic Info
• Top Questions
• Clinical Info
• Interactions

Uses

Diabetes Mellitus

Used as monotherapy for the management of patients with type 2 diabetes mellitus that cannot be controlled by diet alone.

Used in combination with a sulfonylurea, repaglinide, or thiazolidinedione antidiabetic agent for the management of patients with type 2 diabetes who do not achieve adequate glycemic control on monotherapy with metformin or any of these drugs. Used concomitantly with nateglinide in patients who no longer respond adequately to metformin despite appropriate diet, exercise, and metformin monotherapy.

May be used with insulin to improve glycemic control and/or decrease the required dosage of insulin.

Commercially available in fixed combination with glyburide or glipizide for use as initial therapy in the management of patients with type 2 diabetes mellitus whose hyperglycemia cannot be controlled by diet and exercise alone.

Fixed combinations with glyburide or glipizide used as second-line therapy in patients who do not achieve adequate control of hyperglycemia despite therapy with diet, exercise, and initial treatment with a sulfonylurea antidiabetic agent or metformin.

Add a thiazolidinedione antidiabetic agent to metformin in fixed combination with glyburide in patients who have inadequate glycemic control with the fixed combination.

Commercially available in fixed combination with rosiglitazone for the management of type 2 diabetes mellitus in patients who have inadequate glycemic control with metformin monotherapy. Fixed combination with rosiglitazone used in those already receiving therapy with metformin and rosiglitazone as separate components.

Not effective as sole therapy in patients with diabetes mellitus complicated by acidosis, ketosis, or coma.

Dosage and Administration

General

• Sulfonylurea agent may be abruptly discontinued (no transition period generally required) when therapy is transferred from most sulfonylurea antidiabetic agents to metformin.
• Patients whose therapy is transferred from chlorpropamide to metformin should be monitored closely for hypoglycemia during the initial 2 weeks following transfer.
• Goal of therapy should be to reduce both fasting glucose and glycosylated hemoglobin (hemoglobin A_1c [HbA_1c]) values to normal or near normal using the lowest effective dosage of metformin hydrochloride, either when used as monotherapy or combined with another oral antidiabetic agent (e.g., sulfonylurea, acarbose).

Administration

Oral Administration

Administer orally with meals to reduce adverse GI effects.

Administer conventional tablets 2 or 3 times daily. Administer in 2 divided doses if total dosage ≤2 g daily or in 3 divided doses if total dosage is >2 g daily.

Administer extended-release tablets once daily with the evening meal.

Dosage

Individualize dosage carefully based on patient’s glycemic response and tolerance.

Pediatric Patients

Diabetes Mellitus

Oral

Conventional tablets or oral solution in children 10–16 years of age: Initially, 500 mg twice daily with meals as monotherapy. Titrate dosage in increments of 500 mg daily at weekly intervals to a maximum of 2 g daily given in divided doses.

Adults

Diabetes Mellitus

Initial Dosage in Previously Untreated Patients

Oral

Conventional tablets or oral solution: Initially, 500 mg twice daily with the morning and evening meal. Titrate dosage by 500 mg daily at weekly intervals to a total of 2 g daily or to 850 mg twice daily after 2 weeks. Clinically important responses generally not observed at dosages <1.5 g daily. Usual maintenance dosage is 850 mg twice daily.

Alternatively, give initial dosage of 500–850 mg once daily in the morning. If initial dosage is 850 mg daily, titrate dosage by 850 mg daily every other week to a total of 2 g daily.

For additional glycemic control, administer up to a maximum daily dosage of 2.55 g given in divided doses.

Extended-release tablets (Glucophage^® XR) in patients ≥17 years of age: Initially, 500 mg once daily with the evening meal. Titrate dosage by 500 mg daily at weekly intervals to a maximum of 2 g daily. If glycemic control is not achieved with 2 g once daily, consider administering 1 g twice daily. If >2 g daily is required, switch to conventional tablet formulation and increase dosage up to 2.55 g daily in divided doses (preferably 3 doses for daily dosages >2 g).

Extended-release tablets (Fortamet^®) in patients ≥17 years of age: Initially, 1 g daily with the evening meal; 500 mg daily may be used when clinically appropriate. Titrate dosage by 500 mg daily at weekly intervals to a maximum of 2.5 g daily with the evening meal.

Initial Dosage of Metformin Hydrochloride in Fixed Combination with Glipizide (Metaglip^®)

Oral

Initially, 250 mg of metformin hydrochloride and 2.5 mg of glipizide once daily with a meal. For more severe hyperglycemia (fasting plasma glucose concentrations of 280–320 mg/dL), 500 mg of metformin hydrochloride and 2.5 mg of glipizide twice daily. Titrate in increments of one tablet (using the tablet strength at which therapy was initiated) daily at 2-week intervals until adequate blood glucose control is achieved or maximum daily dosage of 2 g of metformin hydrochloride and 10 mg of glipizide is reached.

Efficacy of metformin hydrochloride and glipizide in fixed combination not established in patients with fasting plasma glucose concentrations >320 mg/dL. No experience with total initial daily dosages exceeding 2 g of metformin hydrochloride and 10 mg of glipizide.

Initial Dosage of Metformin Hydrochloride in Fixed Combination with Glyburide (Glucovance^®)

Oral

Initially, 250 mg of metformin hydrochloride and 1.25 mg of glyburide once daily with a meal. For more severe hyperglycemia (i.e., fasting plasma glucose concentrations >200 mg/dL or glycosylated hemoglobin >9%), 250 mg of metformin hydrochloride and 1.25 mg of glyburide twice daily with the morning and evening meal. Titrate dosage in increments of 250 mg of metformin hydrochloride and 1.25 mg of glyburide daily at 2-week intervals adequate control of blood glucose is achieved or a maximum daily dosage of 2 g of metformin hydrochloride and 10 mg of glyburide.

The fixed combination of metformin hydrochloride 500 mg and glyburide 5 mg should not be used as initial therapy due to an increased risk of hypoglycemia.

Initial Dosage in Patients Transferred to Metformin Hydrochloride in Fixed Combination with Glipizide (Metaglip^®)

Oral

In previously treated patients, 500 mg of metformin hydrochloride and 2.5 or 5 mg of glipizide twice daily with the morning and evening meals. The initial dosage of glipizide and metformin hydrochloride in fixed combination should not exceed the daily dosage of metformin hydrochloride or glipizide (or the equivalent dosage of another sulfonylurea) previously received. Titrate dosage in increments not exceeding 500 mg of metformin hydrochloride and 5 mg of glipizide until adequate control of blood glucose is achieved or a maximum daily dosage of 2 g of metformin hydrochloride and 20 mg of glipizide is reached.

For patients switching from combined therapy with separate preparations, the initial dosage of the fixed-combination preparation of glipizide and metformin hydrochloride should not exceed the daily dosages of glipizide (or equivalent dosage of another sulfonylurea antidiabetic agent) and metformin hydrochloride currently being taken. Use clinical judgment regarding whether to switch to the nearest equivalent dosage or to titrate dosage. Titrate dosage in increments of not more than 5 mg of glipizide and 500 mg of metformin hydrochloride until adequate control of blood glucose is achieved or maximum daily dosage of 20 mg of glipizide and 2 g of metformin hydrochloride is reached.

Initial Dosage in Patients Transferred to Metformin Hydrochloride in Fixed Combination with Glyburide (Glucovance^®)

Oral

Initially, 500 mg of metformin hydrochloride and 2.5 or 5 mg of glyburide twice daily with the morning and evening meal. For patients previously receiving metformin hydrochloride or glyburide (or another sulfonylurea agent), the initial dosage of metformin hydrochloride or glyburide should not exceed the dosage (or equivalent dosage) received previously. For patients previously receiving both metformin hydrochloride and glyburide (or another sulfonylurea agent) separately, the initial dosage should not exceed the previous dosage of metformin hydrochloride and glyburide (or the equivalent dosage of the other sulfonylurea) administered separately. Titrate dosage in increments not exceeding 500 mg of metformin hydrochloride and 5 mg of glyburide until adequate control of blood glucose is achieved or a maximum daily dosage of 2 g of metformin hydrochloride and 20 mg of glyburide is reached.

For patients whose hyperglycemia is not adequately controlled on therapy with metformin hydrochloride in fixed combination with glyburide, a thiazolidinedione (e.g., pioglitazone, rosiglitazone) may be added at its recommended initial dosage and the dosage of the fixed combination may be continued unchanged. In patients requiring further glycemic control, titrate thiazolidinedione dosage upward as recommended.

Initial Dosage in Patients Transferred to Metformin Hydrochloride in Fixed Combination with Rosiglitazone (Avandamet^®)

Oral

In patients not adequately controlled on monotherapy with metformin hydrochloride or rosiglitazone, dosage of the fixed combination is based on the patient’s current dosages of metformin hydrochloride and/or rosiglitazone. (See Table.) For replacement of concurrent therapy with the drugs given as separate tablets, dosage of the fixed combination is based on the patient’s current dosages of metformin hydrochloride and/or rosiglitazone.

The tablet strength of the fixed combination that is selected should be the one that most closely provides the patient’s existing dosage of metformin hydrochloride or rosiglitazone, respectively.

Individualize therapy in patients already receiving metformin hydrochloride at dosages not available in the fixed combination (i.e., dosages other than 1 or 2 g).

For patients switching from combined therapy with separate preparations, the initial dosage of the fixed-combination preparation of metformin hydrochloride and rosiglitazone should be the same as the daily dosage of metformin hydrochloride and rosiglitazone currently being taken.

If additional glycemic control is needed following transfer, titrate dosage upward in increments not exceeding 500 mg of metformin hydrochloride and/or 4 mg of rosiglitazone until adequate glycemic control is achieved or a maximum daily dosage of 2 g of metformin hydrochloride and 8 mg of rosiglitazone is reached.

Initial Metformin Hydrochloride Dosage in Patients Transferred from Insulin

Oral

Initially, 500 mg once daily; increase dosage by 500 mg daily at weekly intervals adequate control of blood glucose is achieved or a maximum daily dosage of 2.5 g (conventional tablets) or 2 g (extended-release tablets) is reached. Concurrent insulin dosage initially remains unchanged. When fasting plasma glucose concentration decreases to <120 mg/dL, decrease insulin dosage by 10–25%.

Prescribing Limits

Pediatric Patients

Oral

Children 10–16 years of age: Maximum 2 g daily as conventional tablets or oral solution.

Adults

Oral

Maximum 2.55 g daily (conventional tablets or oral solution; 2.5 g daily as Fortamet^® extended-release tablets; or 2 g daily as certain other extended-release tablets (e.g., Glucophage^®). Switch to conventional tablets for further dosage titration if required dosage exceeds 2 g daily while on extended-release tablets.

For the fixed combination with glyburide, maximum daily dosage as second-line therapy is 2 g of metformin hydrochloride and 20 mg of glyburide. For the fixed combination with glipizide, maximum daily dosage is 2 g of metformin hydrochloride and 20 mg of glipizide. For the fixed combination with rosiglitazone, maximum daily dosage is 2 g of metformin hydrochloride and 8 mg of rosiglitazone.

Special Populations

Geriatric Patients

Maintenance dosage generally should not be titrated to the maximum recommended for younger adults; limited data suggest reducing initial dosage by approximately 33% in geriatric patients.